FDAnews
www.fdanews.com/articles/81267-eisai-signs-in-licensing-agreement-with-dainippon-pharmaceutical-for-potential-new-treatment

EISAI SIGNS IN-LICENSING AGREEMENT WITH DAINIPPON PHARMACEUTICAL FOR POTENTIAL NEW TREATMENT

September 29, 2005

Dainippon Pharmaceutical Co., Ltd (Headquarters: Osaka, President: Kenjiro Miyatake) and Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) today signed an exclusive licensing agreement for AS-3201 (generic name: ranirestat), an investigational drug for the treatment of diabetic neuropathy that was discovered and is being developed by Dainippon Pharmaceutical. Under the agreement, Eisai will assume the exclusive rights to further develop, manufacture and market this compound worldwide outside Japan, while Dainippon Pharmaceutical will retain the rights to Japan and to co-promote the compound with Eisai in major countries.

Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=96584)